A New Type of CPR Announces CPR Therapeutics Inc.

Today CPR Therapeutics Inc. announced they have completed early-phase proof-of-principal studies of its integrated cardiopulmonary resuscitation (CPR) system.  These studies, undertaken at the Halperin Cardiology Bioengineering Laboratory at the Johns Hopkins Hospital, confirmed the Company’s foundational concept that multiple CPR pump mechanisms can be combined to produce dramatic improvements in hemodynamics.

Norman Paradis MD, the Company’s Founder and CEO stated: “We are pleased that these early studies provided such a strong signal of efficacy.  Hemodynamic improvements of this magnitude are unheard of in resuscitation research.  They strongly indicate that we’re on the right track and that our human prototype system will have a positive clinical trial.”  Dr. Paradis is an emergency medicine physician and Professor at the Geisel School of Medicine at Dartmouth.

Dr. Henry Halperin, the Company’s Chief Scientific Officer: “This is very exciting.  While the hypothesis that multiple CPR pump mechanisms might be synergistically combined had face-validity, it is good to see actual data.”  Dr. Halperin is a cardiologist and the David J. Carver Professor of Medicine at Johns Hopkins University.

In a widely used model of cardiac arrest, the Company’s multimodal CPR resulted in more than 50% improvements in indicators of vital organ perfusion.

Dr. Paradis added “improvements like this are predictive of significantly increased rates of successful resuscitation.  We look forward to continuing with our prototype R&D and moving toward clinical trials.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version